with MTIT (24.1% vs. 60.7%, P = 0.005). Wound breakdown was the most common complication in our cohort, which occurred less frequently in the M-MTIT group than in the MTIT group (10.3% vs. 35.7%, P = 0.022). Multivariable logistic regression analysis identified M-MTIT as an independent predictor of reduced risk of wound breakdown. The incidence of other complications, including lymphedema, wound infection and cellulitis was lower in M-MTIT group than in MTIT group; however, the differences did not reach statistical significance. Median follow-up time of this study was 33 months. The Kaplan-Meier survival graphs did not show significant differences in recurrence-free survival and overall survival between the two groups.

Conclusions M-MTIT correlates with lower morbidity rates and does not compromise oncological safety compared with MTIT. It could be considered as a safe and feasible option for vulvar cancer patients with locally advanced disease.

IGCS20_1346

323 ENGOT-EN9/LEAP-001: A PHASE 3 STUDY OF FIRST-LINE PEMBROLIZUMAB PLUS LENVATINIB COMPARED WITH CHEMOTHERAPY IN ADVANCED OR RECURRENT ENDOMETRIAL CANCER

1L Randall*, 2C Marth, 3C Volsteke, 4M Jesús Rubin, 5V Makker, 6I Braicu, 7M Neiches, 8R Madry, 9A Ayhan, 10K Hasegawa, 11X Wu, 12L Dutta, 13C Xu, 14S Keefe, 15J Lee, 16S Pignata. 1Virginia Commonwealth University Medical Center, USA; 2Medical University of Innsbruck, Austria; 3AZ Maria Middelares, Belgium; 4Reina Sofia de Córdoba, Spain; 5Memorial Sloan Kettering Cancer Center, USA; 6Charité Universitätsmedizin, Germany; 7Imperial College, UK; 8University Medycyny im K. Marcinkowskiego w Poznaniu, Poland; 9Ankara Baskent University Hospital, Turkey; 10Saitama Medical University, Japan; 11Fudan University Shanghai Cancer Center, China; 12Eisai Inc., USA; 13Merck and Co., Inc., USA; 14National Cancer Institute, Italy

Background Prognosis and OS are poor in patients with advanced or recurrent endometrial cancer (EC). First-line standard of care for these patients is paclitaxel-carboplatin chemotherapy; however, more effective and tolerable therapies are needed. In the phase 1b/2 trial KEYNOTE-146, which assessed the PD-1 inhibitor pembrolizumab combined with the multitarget kinase inhibitor lenvatinib, an ORR of 38% was observed in patients with previously treated advanced EC. ENGOT-en9/LEAP-001 (NCT03884101) is a randomized, open-label, active-controlled, phase 3 study investigating pembrolizumab + lenvatinib vs chemotherapy in patients with EC.

Trial design Patients with newly diagnosed advanced (stage III-IV) or recurrent EC not previously treated with antiangiogenic agents; systemic chemotherapy (unless within a chemoradiation regimen); PD-1, PD-L1, or PD-L2 inhibitors; or other T-cell receptor–targeted therapies will be eligible. Patients will be randomized 1:1 to receive pembrolizumab 200 mg Q3W + lenvatinib 20 mg daily or paclitaxel 175 mg/m2 Q3W + carboplatin AUC 6 Q3W. Randomization will be stratified by proficient vs deficient mismatch repair (pMMR vs dMMR) status. The pMMR population will be further stratified by prior chemoradiation (yes/no), measurable disease (yes/no), and ECOG performance status (0/1). Patients will receive treatment for ≤35 cycles of pembrolizumab vs 7 cycles of chemotherapy or until initiation of a new anticancer treatment, unacceptable AEs, or withdrawal of consent. Primary endpoints are PFS (per RECIST v1.1 by blinded independent central review) and OS. Secondary endpoints are ORR, health-related QOL, safety/tolerability, and lenvatinib pharmacokinetics. Exploratory endpoints are disease control rate, clinical benefit rate, and duration of response. Enrollment is ongoing.

IGCS20_1347

324 THE COMPLEXITY OF DECISION-MAKING FOR RISK-REducing SURGERY IN WOMEN WITH LYNCH SYNDROME

H. Cun*, D. Nebogen, K. Lu. MD Anderson Cancer Center, USA

Introduction Risk-reducing surgery (RRS) in Lynch Syndrome effectively prevents endometrial and ovarian cancers.
Guidelines recommend discussing prophylactic hysterectomy and bilateral salpingo-oophorectomy (BSO) by age 40–45 for women with MLH1 or MSH2 mutations but lack consensus for timing of surgery. This study aims to define factors that impact decision-making for RRS.

Methods This IRB-approved retrospective study assessed 282 women with Lynch Syndrome with records from 2002–2020. Those preoperatively diagnosed with endometrial hyperplasia or cancer were excluded (n=75). The cohort was divided by mutation and age. Medical history was collected. Comparisons were made with Chi-Squared, McNemar, and Fisher exact tests. Compliance was calculated as the proportion of patients who underwent RRS by the specified age compared to all who met that age.

Results For MLH1 and MSH2 mutation carriers, compliance increased from 47.6% by age 45 to 68.4% by age 50 (p=0.001). Ten patients with prior bowel surgery or pelvic radiation underwent RRS by age 50 compared to 42 patients without this history (p=0.001). Compliance was 41.7% and 80.8% respectively. Surgery by age 50 included: 46 (88.5%) hysterectomy with BSO, 5 (9.6%) hysterectomy alone, and 1 (1.9%) BSO alone. The patient who underwent BSO alone had prior bowel surgery and radiation.

Conclusion The decision to undergo RRS in women with Lynch Syndrome is complex and often individualized. Factors that impact the compliance and timing of surgery include age, mutation status, and prior bowel surgery or pelvic radiation.

Dermatomyositis occurring as a paraneoplastic syndrome in a high grade serous ovarian carcinoma is rare and treating the disease condition is a challenge. A 46-year-old, nulligravid presented with an eight-month history of rash, joint pain, and progressive muscular weakness. Dermatomyositis was diagnosed in the background of cutaneous manifestations, progressive muscle weakness, elevated muscle enzymes and electromyographic findings. She was treated with prednisone, however during the course of...